Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Anteris Technologies Global Corp. ( (AVR) ).
On October 15, 2025, Anteris Technologies Global Corp. announced it received its first European regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve global pivotal trial, known as the PARADIGM Trial, for patients with severe calcific aortic stenosis. This milestone positions Anteris to expand the trial across the United States, Europe, and Canada, with patient recruitment in Denmark expected to begin in the fourth quarter of 2025. The trial aims to assess the safety and effectiveness of the DurAVR® valve compared to commercial TAVR devices, potentially leading to multiple approvals and commercialization opportunities. The announcement marks a significant step in Anteris’s lifecycle, reflecting strong interest from clinicians and the potential to transform care for aortic stenosis patients.
The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
Spark’s Take on AVR Stock
According to Spark, TipRanks’ AI Analyst, AVR is a Neutral.
Anteris Technologies Global Corp. faces significant financial challenges with declining revenues and persistent losses, which heavily impact its overall score. The technical analysis provides a mixed outlook, with some short-term bullish signals but longer-term bearish trends. The valuation is unattractive due to negative earnings and lack of dividends. These factors combine to result in a low overall stock score.
To see Spark’s full report on AVR stock, click here.
More about Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices to restore healthy heart function. The company’s lead product, the DurAVR® Transcatheter Heart Valve (THV), is designed to treat aortic stenosis and is notable for its biomimetic design and use of patented anti-calcification tissue technology.
Average Trading Volume: 162,279
Technical Sentiment Signal: Hold
Current Market Cap: $160.5M
Find detailed analytics on AVR stock on TipRanks’ Stock Analysis page.